Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
18.4M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
345K
-
Shares change
-
-105K
-
Total reported value, excl. options
-
$883K
-
Value change
-
-$269K
-
Number of buys
-
5
-
Number of sells
-
-9
-
Price
-
$2.56
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q3 2023
20 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q3 2023.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 345K shares
of 18.4M outstanding shares and own 1.87% of the company stock.
Largest 10 shareholders include Wellington Shields Capital Management, LLC (153K shares), Wellington Shields & Co., LLC (74.2K shares), VANGUARD GROUP INC (32.4K shares), GEODE CAPITAL MANAGEMENT, LLC (22.2K shares), JANE STREET GROUP, LLC (22.1K shares), FRANKLIN RESOURCES INC (19.8K shares), RENAISSANCE TECHNOLOGIES LLC (17.8K shares), MORGAN STANLEY (1.55K shares), Qube Research & Technologies Ltd (328 shares), and Tower Research Capital LLC (TRC) (327 shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.